Study Reveals Semaglutide's Potential to Slow Aging in Mice
Semaglutide, the active ingredient in popular GLP-1 drugs such as Ozempic and Wegovy, may do more than suppress appetite and improve blood sugar levels. A study funded by the National Institutes of Health (NIH) has found that this drug can reduce several harmful effects associated with aging and extend lifespan in older, healthy mice. Researchers at the University of California, Berkeley, conducted a comparison between semaglutide and calorie restriction, a well-known method for extending lifespan in laboratory animals. The findings revealed that while semaglutide replicated many anti-aging effects of calorie restriction, it also demonstrated additional benefits in critical areas. This raises the intriguing possibility that GLP-1 drugs could directly influence the aging process itself. Previous studies have indicated that these drugs can delay the onset of multiple age-related diseases, suggesting that semaglutide may act on biological mechanisms that drive aging. Rafael de Cabo, Ph.D., a senior investigator at the NIH's National Institute on Aging (NIA), commented on the significance of these findings, stating that most chronic diseases are deeply rooted in the aging process. If GLP-1 agonists can indeed slow down aging, a wide range of clinical benefits would be expected. To explore the effects of semaglutide in a context where aging was already underway, the research team administered the drug to 20-month-old female mice over a three-month period. The results were promising; the treated mice exhibited improved muscle and cognitive function. Additionally, gene activity analyses indicated enhancements in several biological features associated with aging, including reduced inflammation and improved tissue repair and regeneration capabilities. The lifespan outcomes were particularly noteworthy. In a separate group of mice treated with semaglutide until their natural death, the median lifespan was nearly 100 days longer than that of untreated mice. Given that semaglutide reduces appetite, the researchers sought to determine whether the observed anti-aging effects were merely a result of lower calorie intake. To investigate this, they compared semaglutide directly with calorie restriction. One group of 20-month-old female mice received semaglutide, while another group was placed on a 24% calorie-restricted diet designed to match the caloric intake of the treated mice. The two approaches yielded many similar effects, and most physiological measurements remained stable. However, semaglutide exhibited distinct advantages in several areas. Mice receiving the drug showed improvements beyond their initial levels in exploratory behavior, spatial memory, and blood sugar regulation. Their metabolic rates also remained largely unchanged, while the metabolism of calorie-restricted mice slowed down. These differences suggest that semaglutide may engage a biological pathway that operates independently of calorie restriction. Danica Chen, Ph.D., the corresponding author of the study and a professor of metabolic biology and nutrition at UC Berkeley, emphasized the importance of uncovering this potential pathway and the specific benefits it may offer for future longevity-enhancing interventions. While these findings could pave the way for new research directions in longevity, they do not confirm that Ozempic, Wegovy, or other GLP-1 drugs can extend human lifespan. Further clinical research is necessary to determine whether the effects observed in mice can be translated to humans. For instance, a recent post-hoc analysis of the SLIM LIVER trial suggests potential implications, but more studies will be needed to establish whether GLP-1 drugs can significantly influence human aging or longevity. Future clinical studies may also explore the effects of these drugs in healthy older adults. If similar benefits are found in individuals without obesity or diabetes, the potential applications of GLP-1 treatments could expand significantly. This research was supported by NIH through NIA grants R01AG063404, R01AG063389, and R01AG082105. Materials for this study were provided by the NIH/Office of the Director.




